A range of factors, from self-confidence to stress to body weight, can make the difference between taking up exercise or staying on the couch, according to a new study.

Used by several million people worldwide, rosiglitazone (RSG) is an oral agent that helps patients with type 2 diabetes maintain good blood glucose levels by improving how their bodies use insulin.

Abnormal glucose metabolism, which occurs when the body has difficulty processing sugar (glucose) into energy, is twice as common among patients with chronic nerve dysfunction of unknown cause than among the general population and may be a risk factor for the condition, according to a study posted online today that …

The landmark Diabetes Control and Complications Trial (DCCT) funded by the National Institutes of Health, which followed 1,441 people with type 1 diabetes for a decade until 1993, showed conclusively that tight blood glucose control significantly reduces the risk of developing complications of diabetes such as eye, kidney and nerve …

Nerve signals relayed directly to the pancreas after eating a meal play a critical role in normal blood sugar control, according to a report in the June 7, 2006, Cell Metabolism. Therefore, drugs that increase the sensitivity to such signals might offer a new approach to diabetes treatment, the researchers …

Scientists at Joslin Diabetes Center have discovered that a surprisingly high percentage of people with type 1 diabetes (insulin-dependent) who have had the disease for 50 years or longer (The Joslin Medalists) may still have residual functioning, insulin-producing islet cells and/or islet cell antibodies.

The offspring of women with pregestational diabetes, either type 1 or type 2, are at a three-fold increased risk for perinatal mortality, and a two-fold increased risk for congenital anomalies, compared with the general population.

Body mass index (BMI), the ratio of body weight to height, is tightly linked to lifetime risk of diabetes.

A serendipitous finding was that the children tend to become very involved in their own diabetes management when using a continuous blood glucose monitor.

Galvus, a new once-daily oral treatment option for type 2 diabetes, lowers A1c 2.8% and demonstrates impressive efficacy, especially in patients with poor glycemic control, as well as weight loss benefits in obese patients.